前列腺、肺、结肠和卵巢（PLCO）癌筛查试验：现状与前景。

The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.

作者信息

Andriole Gerald L, Reding Douglas, Hayes Richard B, Prorok Philip C, Gohagan John K

机构信息

Division of Urologic Surgery, Washington University School of Medicine, Washington University in St. Louis, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA.

出版信息

Urol Oncol. 2004 Jul-Aug;22(4):358-61. doi: 10.1016/j.urolonc.2004.04.013.

DOI:10.1016/j.urolonc.2004.04.013

PMID:15283897

Abstract

The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.

摘要

前列腺、肺癌、结直肠癌和卵巢癌筛查试验是一项随机、多中心研究，旨在评估对前列腺癌、肺癌、结肠癌和卵巢癌进行筛查是否会降低癌症特异性死亡率。已确定了超过15.5万名参与者，并将对他们进行监测，直至2015年。已建立了一个对筛查个体和对照参与者的生物样本库。来自干预组和对照组的数据以及生物样本库中的材料共同构成了一种宝贵资源，可用于识别和测试人类疾病的新型生物标志物。